BRCA1 and prostate carcinoma: Contributions of molecular diagnostics and next-generation sequencing being a new era of prostate cancer testing for Novel genetic biomarkers, like BRCA1/2, HOXB13, ATM, CHEK2, and DNA mismatch repair (MMR) genes, provide insight into inherited risk, disease progression, and targeted therapies [4].